2007 Methodology used for the production of the Canadian.

Slides:



Advertisements
Similar presentations
Participation Requirements for a Guideline Panel Member.
Advertisements

Susan Tallett MB BS MEd FRCPC Professor of Paediatrics Member Safety Competencies Steering Committee June 2008 – PS Working Group Paediatric Chairs of.
2001 Canadian Hypertension Education Program Recommendations 1 Focus on the 2001 Canadian Recommendations for the Management of Hypertension Version: April.
Participation Requirements for a Guideline Panel Co-Chair.
Participation Requirements for a Patient Representative.
JNC 8 Guidelines….
Disease State Management The Pharmacist’s Role
Participation Requirements for a Guideline Panel PGIN Representative.
Improving Diagnosis and Management of Hypertension: Implementation of Ambulatory Blood Pressure Monitoring in Primary Care* Scot B. Sternberg, MS; Kristine.
TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER Libraries of The Health Sciences MSIII’s Internal Medicine Clerkship Point of Care Evidence Based Medicine.
2014 Survey on Living with Chronic Diseases in Canada (SLCDC): Mood & Anxiety Disorders National Mental Health and Addictions Information Collaborative.
Canadian Diabetes Association Clinical Practice Guidelines Treatment of Hypertension Chapter 25 Richard E. Gilbert, Doreen Rabi, Pierre LaRochelle, Lawrence.
Azara Proprietary & Confidential Controlling High Blood Pressure 2014 Measure Changes Improving Patient Outcomes through Data.
Pan Canadian Hypertension Framework
Strengths and challenges of the CPG development process: Canadian Society of Nephrology Marcello Tonelli MD SM Chair, CSN-CPG Committee.
1. Best Practices in the Prevention and Control of Hypertension Globally and Putting Evidence into Practice Mark Niebylski, PhD, MBA, MS October 22, 2014.
Clinical Pharmacy Basma Y. Kentab MSc..
A guide for healthcare professionals Measuring Blood Pressure at Home Michigan Department of Community Health Heart Disease and Stroke Prevention Unit.
HYPERTENSION The Alabama Department of Public Health’s Hypertension Program.
TRANSLATING VISITS INTO PATIENTS USING AMBULATORY VISIT DATA (Hypertensive patient case study) by Esther Hing, M.P.H. and Julia Holmes, Ph.D U.S. DEPARTMENT.
Nova Scotia Falls Prevention Update Preventing Falls Together Conference October 29, 2009 Suzanne Baker.
Basma Y. Kentab MSc.. 1. Define ambulatory care 2. Describe the value of ambulatory care practices 3. Explore pharmacy services in some ambulatory care.
NN/LM National Initiatives Pacific Southwest Region May 15 th, 2013 Midday at the Oasis.
TOBACCO CONTROL INITIATIVE HCSD Disease Management Program Quarterly Meeting April 26, 2005 Sarah Moody Thomas, PhD Statewide Clinical Lead.
Process for Guideline Development in Canada 2011 Canadian Hypertension Education Program Recommendations.
Brief summary of the GRADE framework Holger Schünemann, MD, PhD Chair and Professor, Department of Clinical Epidemiology & Biostatistics Professor of Medicine.
Peter Emery, MD Specialist in Clinical Hypertension InterMed Portland, ME.
Health Statistics Information on STC website Calgary–DLI training–Dec 2003 Michel B. Séguin, Statistics Canada,
10 Points to Remember on An Effective Approach to High Blood Pressure ControlAn Effective Approach to High Blood Pressure Control Summary Prepared by Debabrata.
Can pharmacists improve outcomes in hypertensive patients? Sookaneknun P (1), Richards RME (2), Sanguansermsri J(1), Teerasut C (3) : (1)Faculty of Pharmacy,
Organization and guideline development April 2010 ACCC The Netherlands.
Should developing countries continue to use older drugs for essential hypertension? A prescription survey in South Africa suggested that prescribers were.
ATSHO/National Forum Policy, Environmental and Program Strategies to Diagnose, Treat, and/or Control Hypertension Featuring Examples from the 2014 Million.
BMH CLINICAL GUIDELINES IN EUROPE. OUTLINE Background to the project Objectives The AGREE Instrument: validation process and results Outcomes.
Basic Nursing: Foundations of Skills & Concepts Chapter 9
Hypertension Family Medicine Specialist CME October 15-17, 2012 Pakse.
Using drug use evaluation (DUE) to optimise analgesic prescribing in emergency departments (EDs) Karen Kaye, Susie Welch. NSW Therapeutic Advisory Group*
WHO GUIDANCE FOR THE DEVELOPMENT OF EVIDENCE-BASED VACCINE RELATED RECOMMENDATIONS August 2011.
Vascular Health Coalition Healthy Menu Checklist Implementation Guide (Companion to the Healthy Menu Checklist provided separately) For more information.
Improving Clinical Processes: The Million Hearts ® Hypertension Control Change Package for Clinicians Erica K. Taylor, PhD, MPH, MA Million Hearts ® Minority.
Indicators in Malaria Program Phases By Bayo S Fatunmbi [Technical Officer, Monitoring & Evaluation] ERAR-GMS, WHO Cambodia & Dr. Michael Lynch Epidemiologist.
Section VII. Home BP Measurement 2015 Canadian Hypertension Education Program Recommendations.
1 Dissemination and Implementation Paul K. Whelton MD, MSc for the ALLHAT Collaborative Research Group ALLHAT U.S. Department of Health and Human Services.
From the initial page of the Cochrane Library, we have clicked on the Cochrane Reviews: By Topic hyperlink. This has displayed the Topics for Cochrane.
2007 Hypertension as a Public Health Risk January, 2007.
Canadian Best Practice Recommendations for Stroke Care Recommendation 1: Public Awareness and Patient Education (Updated 2008)
Stroke epidemic in Pakistan Mohammad Wasay, MD, FRCP, FAAN Aga Khan University.
Uses of the NIH Collaboratory Distributed Research Network Jeffrey Brown, PhD for the DRN Team Harvard Pilgrim Health Care Institute and Harvard Medical.
Standards and Competencies for Cancer Chemotherapy Nursing Practice in Canada: CANO/ACIO AN INTRODUCTION.
Presentation Developed for the Academy of Managed Care Pharmacy
Depression Screening in Primary Care and Impact on Suicide Prevention Anne-Marie T. Mann, BSN, RN, DNP Candidate Diane Kay Boyle, PhD, RN, FAAN.
Prevent a Fall Before it Happens Presented By:. 2 2 What do they have in common?
Clinical Quality Improvement: Achieving BP Control
Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults  Alexander A. Leung, MD, MPH,
Management of Hypertension according to JNC 7
Impact and costing of cardiovascular disease treatmentin Kwara State Health Insurance (KSHI) program. University of Ilorin Teaching Hospital (UITH) Amsterdam.
The 2011 Canadian Hypertension Education Program Recommendations for the Management of Hypertension: Blood Pressure Measurement, Diagnosis, Assessment.
The 2015 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment.
The 2012 Canadian Hypertension Education Program Recommendations for the Management of Hypertension: Blood Pressure Measurement, Diagnosis, Assessment.
Introduction to Clinical Pharmacy
Systematic Review, Synthesis, & Clinical Practice Guidelines
Hypertension Canada’s 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children  Kara A. Nerenberg,
CNISP & CIHI MRSA infection rate comparison Preliminary results
Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention,
The 2015 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment.
The 2011 Canadian Hypertension Education Program Recommendations for the Management of Hypertension: Blood Pressure Measurement, Diagnosis, Assessment.
The 2014 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of.
Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults  Alexander A. Leung, MD, MPH,
The 2012 Canadian Hypertension Education Program Recommendations for the Management of Hypertension: Blood Pressure Measurement, Diagnosis, Assessment.
The 2013 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment.
Presentation transcript:

2007 Methodology used for the production of the Canadian

Canadian Hypertension Education Program Recommendations 2007 Canadian Hypertension Education Program CHEP recommendations are based on critically evaluated clinical trial evidence and highly value improved patient outcomes Use of CHEP recommendations in clinical practice requires an integration of the recommendations with –Individual patient characteristics and preferences –A consideration of the costs of therapy

Canadian Hypertension Education Program Recommendations Slide kits, clinical practice algorithms and supporting literature for full recommendations can be downloaded from Canadian Hypertension Education Program

Canadian Hypertension Education Program Recommendations Canada has had annually updated evidence-based recommendations since The CHEP process was initiated in 2000 as part of a national strategy to improve blood pressure control in Canada. The 2000 process was linked to the periodic update of lifestyle and hypertension management recommendations in The production of recommendations are linked a separate and specific implementation plan and to an evaluation strategy. Canadian Recommendations for the Management of Hypertension

2007 Canadian Hypertension Education Program Recommendations 5 CHEP Organizational Chart Outcomes Research Task Force Evidence-Based Recommendations Task Force ________________ Central Review Committee Implementation Task Force Steering Committee Executive Committee Topic subgroups

2007 Canadian Hypertension Education Program Recommendations 6 STEERING COMMITTEE: N Campbell (Chair), M Lebel (CHS), R Petrella (CFPC, BP Canada), S Samis (HSFC), G Taylor (PHAC), S Matheson (CCCN), L Poirier (CPA), D Drouin, J Kaczorowski, J Onysko, S Tobe, R Touyz EXECUTIVE COMMITTEE: N Campbell (Chair), D Drouin, J Kaczorowski, J Onysko, S Tobe, R Touyz (to 2006) R Lewanczuk (from 2006) CENTRAL REVIEW COMMITTEE: B Hemmelgarn (Co-Chair), F McAlister (Co-Chair), N Khan, R Padwal, M Hill, J Mahon Canadian Hypertension Education Program 2007

2007 Canadian Hypertension Education Program Recommendations 7 Sponsoring organizations and partners Sponsoring organizations –Canadian Hypertension Society –Blood Pressure Canada –Public Health Agency of Canada –Heart and Stroke Foundation of Canada –College of Family Physicians of Canada –Canadian Council of Cardiovascular Nurses –Canadian Pharmacy Association Partner organizations –Canadian Cardiovascular Society –Canadian Society of Nephrology –Canadian Stroke Network –Canadian Society of Internal Medicine –Kidney Foundation of Canada Volunteers (>90)

2007 Canadian Hypertension Education Program Recommendations 8 Financial Support Pharmaceutical Sponsors of CHEP are: Abbott Laboratories Merck Frosst Canada AstraZeneca Novartis Bayer HealthCare Pfizer Canada Biovail Pharma Sanofi-Aventis Boehringer Ingelheim Servier Canada Bristol-Myers Squibb Solvay Pharma CHEP is financially supported by the Public Health Agency of Canada and the Canadian Hypertension Society. CHEP receives indirect support from the Heart and Stroke Foundation and Blood Pressure Canada CHEP outcomes studies have been supported by the Public Health Agency of Canada, Canadian Institute for Health Research and the Heart and Stroke Foundation

Canadian Hypertension Education Program Recommendations CHEP - MINIMIZING BIAS CHEP recognizes bias as a serious threat to recommendations processes and takes multiple steps to reduce its impact. Overt steps taken to reduce bias include. 1) A history of requiring a high level of evidence with patient outcomes for pharmacotherapy recommendations 2) A centralized systematic literature review 3) Multiple members in subgroups to represent different views

Canadian Hypertension Education Program Recommendations CHEP- MINIMIZING BIAS 4) A Central Review Committee (CRC) that is ‘free of COI’ to oversee the evaluation of evidence, development of recommendations and to present the evidence/ recommendations 5) Overt written disclosure of potential COI at the time of the development of the recommendations 6) A consensus approach to the drafting of the recommendations chaired by the CRC 7) Voting on recommendations with the removal of recommendations voted against by 30% of members.

Canadian Hypertension Education Program Recommendations CHEP- MINIMIZING BIAS 8)Themes, key messages and major implementation tools are developed through a consensus of the full executive. Other internal implementation tools require the consensus of two members of the executive. 9)External implementation tools must be completely consistent with the content and intent of CHEP recommendations and require a consensus of 3 members of the executive. The CHEP executive prioritized minimizing the potential impact of bias at it’s business planning retreat in May 2006.

Canadian Hypertension Education Program Recommendations METHODOLOGY the production of recommendations Can J Cardiol 2006;22:559-64

Canadian Hypertension Education Program Recommendations Recommendations Task Force: S Tobe (Chair), R Lewanczuk (Vice-chair) Accurate Measurement of BP: C Abbott (Chair), K Mann, L Cloutier Adherence Strategies for Patients: R Feldman (Chair), A Milot; J Stone, T Campbell Follow-up of BP: P Bolli (Chair), G Tremblay Risk Assessment: S Grover (Chair), G Tremblay, A Milot Self-measurement of BP: D McKay (Chair), A Chockalingam Ambulatory BP Monitoring: M Myers (Chair), S Rabkin, M Dawes Routine Laboratory Testing: T Wilson (Chair); B Penner, E Burgess Echocardiography: G Honos (Chair) Lifestyle Modification: R Touyz (Chair), N Campbell, N Gledhill, R Petrella, L Trudeau Pharmacotherapy of Hypertension in Patients Without Other Compelling Indications: F McAlister (Chair), G Carruthers, J DeChamplain, G Fodor, P Hamet, R Herman, G Pylypchuk Pharmacotherapy for Hypertension in patients with Cardiovascular Disease: S Rabkin (Chair), M Arnold, G Moe, Jean-Martin Boulanger Diabetes: P Larochelle (Chair), L Leiter, R Ogilvie, C Jones, S Tobe, V Woo, P McFarlane Renal and Renovascular HTN: S Tobe (Chair), B Culleton, K Burns, M Ruzicka Endocrine forms of hypertension: E Schiffrin (Chair) Vascular Protection: R Feldman (Chair), R Hegele, P McFarlane Canadian Hypertension Education Program

Canadian Hypertension Education Program Recommendations Evidence Based Recommendations Task Force Subgroups Office Measurement of BP Follow-up of BP Risk Assessment Self-measurement of BP Ambulatory BP Monitoring Routine Laboratory Testing Echocardiography Lifestyle Modification Pharmacotherapy of Hypertension in Patients Without Other Compelling Indications Pharmacotherapy for Hypertension in patients with Cardiovascular Disease Diabetes and Hypertension Renal and Renovascular Hypertension Endocrine forms of Hypertension Concordance Strategies for Patients Vascular Protection

Canadian Hypertension Education Program Recommendations 2007 Canadian Hypertension Education Program : The process Subgroups systematically review the literature using a Cochrane librarian and supplement the search with personal files to Sept 2006 Application of an evidence-based grading scheme Use of a Central Review Committee comprised of methodologists to improve consistency of grading 1 day conference to discuss recommendations and evidence (Sept 2006) National presentation of draft recommendations (Canadian Cardiovascular Congress Vancouver, Oct 2006) Voting and ratification of recommendations achieving >70% acceptance

Canadian Hypertension Education Program Recommendations 2007 Canadian Hypertension Education Program Detailed methodology of the system to grade evidence can be found in Can J Cardiol 2006;22:559-64

Canadian Hypertension Education Program Recommendations Level of evidence used by the CHEP (2000) Adequate randomized controlled trial (RCT) or subgroup analysis OR systematic review of adequate RCT with similar Rx arms None of the above D Validated surrogate outcome measure OR extrapolation of results from another population Clinically relevant mortality or morbidity outcome measure and representative population Validated surrogate outcome measure OR extrapolation of results from another population ApplicabilityPrecision Internal validityGrade Studies in which the 95% confidence intervals do not exclude meaningful contrary conclusions Inadequate statistical power to exclude clinically important differences OR systematic review with heterogeneity Statistically significant results OR adequate statistical power to exclude clinically important differences Inadequate RCT or subgroup analysis OR cohort/case controlled studies OR systematic review of RCT with Rx arms from different studies C Adequate RCT or subgroup analysis OR systematic review of similar RCT using similar Rx arms B A

Canadian Hypertension Education Program Recommendations METHODOLOGY the implementation of recommendations Can J Cardiol 2006;22:595-98

Canadian Hypertension Education Program Recommendations 2007 Canadian Hypertension Education Program Implementation Task Force: D Drouin (Chair), J Kaczorowski (Vice- chair) Nurses Sub-group: Jo-Anne Costello, Kori Kingsbury, Sandra Matheson Pharmacists Sub-group: Luc Poirier, Bill Semchuk, Ross Tsuyuki Family Physicians Sub-group: Martin Dawes, John Hickey, Rob Petrella Members at large: Jean-Martin Boulanger, Norm Gledhill, Ross Feldman, Norm Campbell, Sheldon Tobe, Alain Milot, Guy Tremblay, Rhian Touyz, Jay Onysko, Rick Ward

Canadian Hypertension Education Program Recommendations 2007 Canadian Hypertension Education Program An important function of the CHEP executive is the development and updating of key CHEP implementation tools Implementation of CHEP recommendations is a task for all CHEP members

Canadian Hypertension Education Program Recommendations 2007 Canadian Hypertension Education Program Between 2001 and 2005, The College of Family Physicians of Canada, The Canadian Pharmacy Association and the Canadian Council of Cardiovascular Nurses joined the CHEP steering committee to oversee the integrity and relevance of the process for their disciplines and to aid dissemination In 2005 specific subgroups of nurses, pharmacists and family doctors were formed to tailor the tools and messages to their discipline and develop dissemination strategies and networks within their discipline.

Canadian Hypertension Education Program Recommendations Some annual dissemination initiatives Key messages and themes are updated annually Publications (3-4 summaries plus full scientific documents) with more than 40 publications by or on CHEP in 2006 CHEP pocket cards (140000) and booklets ( ) Dissemination through the websites Wall posters CHEP's "Train the Trainer" Sessions

Canadian Hypertension Education Program Recommendations Some annual dissemination initiatives Management algorithms Power point slide sets Palm application Endorsement or co-development of education programs with RxD companies Media releases with HSF Development of HCP networks (family doctors, nurses and pharmacists)

Canadian Hypertension Education Program Recommendations 2007 Canadian Hypertension Education Program A slide kit and other educational resources can be downloaded from

Canadian Hypertension Education Program Recommendations In the slide kit, special color codes have been associated with specific types of information. Here are some examples: Do not Explanation, Statement, or List Recommendation Important comment, Warning Reminder Do not 2007 Canadian Hypertension Education Program A red flag is been posted where recommendations were updated for 2007.

Canadian Hypertension Education Program Recommendations Multidisciplinary Executive Summaries Canadian Hypertension Recommendations. “What’ new and what’s old but still important”. One page - clinical 4 page - clinical 6 page - scientific

Canadian Hypertension Education Program Recommendations METHODOLOGY the evaluation of recommendations Can J Cardiol 2006;22:

Canadian Hypertension Education Program Recommendations Outcomes Research Task Force An Outcomes Research Task Force was developed to assess the impact of CHEP on hypertension management Details of the Task force can be found in Can J Cardiol 2006;22:

Canadian Hypertension Education Program Recommendations 2007 Canadian Hypertension Education Program Ernest AmankwahGillian BartlettTari Bhattia Rollin BrantDenis Drouin (Ex Officio)Michael Eliasziw Bill GhaliBrenda HemmelgarnRu-Nie Gao Steven GroverNadia KhanMichael Hill Helen JohansenRaj PadwalColleen Maxwell Finlay McAlisterMark SmithStephen Phillips Hude QuanKaren TuLarry Svenson Greg TaylorJennifer ZhangAndy Wielgosz Kelly Zarnke Outcomes Research Task Force: N Campbell (Chair), J Onysko (Vice-chair)

Canadian Hypertension Education Program Recommendations Outcomes Research Task Force ORTF Collaborative effort with PHAC, Statistics Canada, provinces and organizations to develop a national surveillance system for hypertension 1)Physical Measures Surveys 2)IMS Health Compuscript data 3)Provincial Administrative Databases 4)National Questionnaire Surveys (CCHS, NPHS) 5)National Hospitalization and Mortality Data

Canadian Hypertension Education Program Recommendations Physical Measures Surveys Ontario HSF will have results of an Ontario physical measures survey assessing hypertension prevalence, awareness, treatment and control in 2007 Statistics Canada will have results of a national physical measures survey assessing hypertension prevalence, awareness, treatment and control in 2009

Canadian Hypertension Education Program Recommendations Changes in antihypertensive prescriptions in Ontario using IMS Compuscript data Hypertension 2006; 47:22-28

Canadian Hypertension Education Program Recommendations Changes in initiation of antihypertensive prescriptions in elderly Ontarians using provincial administrative data Hypertension 2006; 47:22-28

Canadian Hypertension Education Program Recommendations National Questionnaire Surveys (CCHS, NPHS) Large national questionnaire surveys Results are representative of the Canadian population

2007 Canadian Hypertension Education Program Recommendations 35 Changes in diagnosis of hypertension in Canada Post 1999 compared to pre 1999 Doubling of the rate of diagnosis of hypertension Closing of the gender gap Hypertension 2006;48:853-60

2007 Canadian Hypertension Education Program Recommendations 36 Changes in the treatment of hypertension Post 1999 compared to pre 1999 Doubling of the rate of treatment of hypertension Closing of the gender gap Hypertension 2006;48:853-60

2007 Canadian Hypertension Education Program Recommendations 37 Changes in the proportion of those diagnosed that are not treated Post 1999 compared to pre 1999 Marked decrease in proportion of aware hypertensives that are untreated Closing of the gender gap. Hypertension 2006;48:853-60

Canadian Hypertension Education Program Recommendations 2007 Canadian Hypertension Education Program CHEP NOW HAS THE ABILITY TO IDENTIFY MANAGEMENT ISSUES Almost 50% of women over age 60 are on drug therapy A low proportion of younger hypertensives are on drug therapy More than 10% of uncomplicated elderly hypertensives are started on Beta Blocker therapy.

Canadian Hypertension Education Program Recommendations Canada has had continuously updated hypertension management recommendations since 1999 A rigorous methodology is used to ensure the recommendations are reliable An extensive implementation process is used to ensure tools are available to aid uptake of the recommendations in clinical practice The evaluation process is still being established but preliminary data support a large increase in diagnosis and treatment of hypertension associated with a reduction in cardiovascular complications 2007 Canadian Hypertension Education Program

Canadian Hypertension Education Program Recommendations CHEP New Initiatives To translate the hypertension recommendations and disseminate to the public and patients with hypertension. (A partnership with Blood Pressure Canada, Canadian Hypertension Society, the Heart and Stroke Foundation and the World Hypertension League (World Hypertension Day)) Linking to community based programs and local hypertension/ atherosclerosis clinics to facilitate the update of hypertension best management programs